Articles tagged with Metastasis
Researchers at IRB Barcelona have discovered the MAF gene is a reliable predictor of breast cancer bone metastasis. The study, published in JNCI, analyzed over 900 clinical samples and found that MAF-altered tumors are 14 times more likely to develop bone metastasis.
A new report by Eliezer Van Allen and colleagues found that melanoma patients who benefit from ipilimumab immunotherapy have unique tumor-produced antigens. The study suggests that predicting which patients will respond to the treatment may be challenging due to differences in molecular targets.
A University of Colorado Cancer Center study found that 41% of open lung cancer clinical trials excluded patients with previously treated CNS disease, while 26% allowed those with untreated CNS involvement. The study suggests that current practice may be based on habit rather than scientific rationale.
Researchers found that microRNA 506 acts as a tumor suppressor in gastric cancer, inhibiting angiogenesis and metastasis. Patients with high miR-506 expression have significantly longer survival times compared to those with low expression levels.
Researchers analyzed data from patients undergoing stage IV colorectal cancer surgery to identify benchmarks for surgical practice. They found that major complications vary depending on the extent of liver resection and type of colorectal surgery performed.
Researchers have discovered that a type of jumping gene called LINE-1 is actively inserted into the human genome in various gastrointestinal cancers. The findings suggest that these insertions may occur early in cancer development and could potentially serve as a marker for early cancer diagnosis.
E-Cad protein facilitates coordinated movement of diverse cell types, enabling them to migrate together and distribute at their destination. This new function may explain why tumours with intermediate E-Cad levels have a poorer prognosis, highlighting the protein's role in cancer metastasis.
Researchers at Case Western Reserve University have developed a magnetic resonance imaging (MRI) contrast agent that can detect small aggressive breast cancer tumors and micrometastases. The agent binds to molecular markers expressed in high-risk primary tumors and metastases, generating increased image contrast.
Researchers at UC Davis found that a novel combination therapy of Interleukin (IL)-2 combined with imiquimod and topical retinoid is highly effective in treating patients with skin metastases, resulting in complete clinical response and high survival rates.
Researchers discovered that blocking a specific ion channel in medulloblastoma can impede tumor cells from proliferating and spreading. The development of targeted treatments could improve outcomes for patients with this disease, which is a common cause of death in children.
Scientists at Johns Hopkins Medicine identified a molecular partnership between annexin A2 and Sema3D that helps explain how pancreatic cancer spreads. Annexin A2, already linked to poor survival rates, guides the release of Sema3D, which fuels the cancer's spread by tracking nerve cells.
Researchers at Boston University School of Medicine have identified a new molecule named IL13RA2 as a potential marker for metastatic basal-like breast cancer (BLBC). The discovery suggests that targeting this molecule could slow tumor growth and spread, offering a glimmer of hope for patients with this aggressive form of breast cancer.
Researchers have developed a genetic test that analyzes tumor sensitivity to radiation therapy, with findings suggesting metastatic colon tumors are more resistant to radiation than primary tumors. The study suggests personalizing radiation therapy for patients may be possible through this test.
The foundation awarded four-year fellowships to 16 postdoctoral scientists conducting innovative cancer research, providing them with independent funding to work on novel projects. The recipients aim to understand cell migration, protein crowding, and gene expression in cancer cells.
Scientists designed nanoparticles that release chemotherapy drugs paclitaxel in the presence of matrix metalloproteinases (MMPs), which enable cancer metastasis. The system effectively delivers high doses of the drug, halting tumor growth and reducing toxicity.
Scientists have identified key genetic mutations leading to skin cancer progression, similar to those found in human cancers. By analyzing genetic abnormalities in premalignant and fully malignant tumors, researchers found that larger chromosomal copy number alterations were responsible for tumor formation, rather than point mutations.
Researchers at Thomas Jefferson University discovered DNA-PKcs as a central regulator of metastatic processes in prostate cancer. The kinase modulates signaling networks that turn on metastatic processes, and its levels can predict poor outcomes in patients. A potential drug inhibitor, CC-115, is currently being tested in clinical trials.
Patients with metastatic colorectal cancer (mCRC) and quadruple wild-type genes showed significant benefit from continuing anti-EGFR therapy beyond progression. Second-line cetuximab plus FOLFOX chemotherapy improved progression-free survival, response rate, and overall survival in patients without genetic mutations.
A phase IIIb study has confirmed regorafenib's benefit in patients with previously treated metastatic colorectal cancer. The safety profile and progression-free survival were similar to phase III trial results, with a median duration of 2.5 months.
MD Anderson researchers discovered a breast tumor marker that predicts metastasis by analyzing the gene expression signature of mouse embryos. Tumors with similar signatures to six-day-old embryos were more prone to metastasize than those with adult-like signatures.
Researchers have discovered a gene called SMOC-2 that plays a crucial role in the spread of colorectal cancer. Increased levels of SMOC-2 enable tumor cells to 'leave home' and metastasize, while blocking its activation inhibits metastasis. The gene's expression patterns also resemble those of healthy intestinal stem cells.
Researchers found that lymph node metastases do not require new blood vessels but instead use existing ones, providing a mechanism for resistance to angiogenic therapies. The study suggests alternative treatments may be needed for patients at risk of lymph node metastasis.
A study found that 86% of women with early-stage breast cancer in Ontario underwent imaging to detect metastatic cancer, despite international guidelines recommending against it. The use of advanced imaging increased and varied by geographic region and hospital type, highlighting a need for improved knowledge translation strategies.
A study published in JNCI found that women with tubal ligation who develop aggressive endometrial cancer types have lower mortality rates. The researchers suggest that TL reduces cancer cell passage through the fallopian tubes, lowering disease stage and mortality.
The newly redesigned Oncology Central is now live, featuring a dedicated Pipelines and Trials section, webinars, and exclusive multimedia content. The platform offers easy navigation and access to peer-reviewed journal articles, regular cancer news updates, and exciting features.
The Harvard Medical School Cancer Biology and Therapeutics Training Program will provide specialized education and training in cancer research and treatment. The one-year, nonclinical blended-learning certificate program is designed to promote a deeper understanding of cancer biology, diagnosis, and personalized treatments.
Researchers identified two genes, ERCC1 and TS, that can predict positive response to chemotherapy and longer survival times in metastatic colorectal cancer patients. Low levels of these genes are associated with improved survival rates when treated with oxaliplatin, while high levels may require irinotecan as the first treatment choice.
A study by researchers at Lund University found that high levels of ALK1 protein in blood vessels increase the risk of metastases. The drug Dalantercept can prevent this spread by blocking ALK1, offering new hope for breast cancer patients.
Researchers found that high levels of ALK1 protein in breast tumor vasculature correlate with increased risk of metastatic disease. An investigational drug targeting ALK1 prevented disease spread in preclinical studies, offering a potential new therapeutic approach for treating metastatic breast cancer.
Min Yu, a USC stem cell researcher, has been named a Pew-Stewart scholar for her work on metastatic breast cancer. She aims to identify molecular adaptations and genetic mutations that allow circulating tumor cells to establish new tumors throughout the body.
Researchers unveiled innovative approaches to cancer treatment and malaria vaccination at the 2015 AAPS National Biotechnology Conference. Dual antibody-coated nanomaterials show promise in capturing circulating tumor cells, while penfluridol suppresses pancreatic tumor growth through autophagy-mediated apoptosis.
A team of researchers from the University of South Florida doubled survival time in an aggressive metastatic cancer model using a novel combination of ketogenic diet and supplements with hyperbaric oxygen therapy. The study shows beneficial effects of ketone supplements in conjunction with non-toxic therapeutic regimens.
Researchers used PET/CT with Ga-68 DOTATOC to detect primary tumors in patients with metastatic neuroendocrine cancer. The study found that 28% of patients underwent a major change in cancer management due to the imaging technique.
Researchers at Arizona State University identify five foundations of multicellularity that cancer cells bypass to fulfill their selfish needs, leading to disastrous outcomes for the organism. The study provides clues about how to diagnose and treat cancer, a disease with rapid evolution capabilities.
Researchers from Mount Sinai Health System will present updates on a lymphoma vaccine clinical trial and new treatment strategies in relapsed multiple myeloma. Preliminary results show patients achieving partial or complete clinical remissions, including those with advanced stage disease.
A large study has found that whole brain radiation therapy (WBRT) significantly worsens cognitive function compared to radiosurgery, and should no longer be used in the adjuvant setting after radiosurgery. WBRT's side effects include hair loss, fatigue, and significant interruptions in systemic therapy.
The PALOMA-3 study found that palbociclib significantly extended progression-free survival for women with hormone-receptor-positive metastatic breast cancer, reducing cancer recurrence by 25% compared to chemotherapy alone. The treatment was well-tolerated and improved quality of life, offering a new hope for women with advanced disease.
Genetically programmed probiotics can detect liver cancer metastases early-on by producing signals easily detectable in urine. The approach may be useful for detecting the disease earlier, increasing chances of survival.
A phase I/II clinical trial found that brigatinib responded to treatment in 58 of 78 ALK+ patients, with a 13.4-month progression-free survival rate for those previously treated with crizotinib. Brigatinib also showed promise in treating brain metastases, with a 30% decrease in tumor size and controlled disease for 15.6 months.
A phase 3 international trial found that ipilimumab improved recurrence-free survival in advanced stage melanoma patients who underwent surgical resection. The study showed that patients with microscopic metastatic disease responded best to ipilimumab treatment.
Researchers have identified a molecule, PMEPA1, that promotes metastasis of advanced prostate cancer to the bone, which can lead to incurable conditions. The discovery may offer new targets for diagnosing and treating prostate cancer.
Researchers developed a new micro-device that separates and analyzes highly mobile cancer cells, which are believed to be the more aggressive cells responsible for metastasis. The study aims to gain an understanding of what makes some cancer cells able to spread to other areas of the body.
A study published in Nature Cell Biology reveals that exosomes secreted by pancreatic cancer cells contain MIF, which educates liver cells to produce a protein leading to fibrosis and tumor growth. This discovery could lead to targeted treatments and biomarkers for early detection.
Researchers developed a microfluidic chip to capture CTC clusters from whole blood, revealing their prevalence and potential role in metastasis. The Cluster-Chip captured 30-40% of patients' CTC clusters, offering new insights into cancer biology and potentially leading to breakthroughs in cancer research.
Researchers developed a microfluidic device called the Cluster-Chip to capture clusters of two or more cells, which are significantly more likely to cause metastases. The device proved 40-50% better at finding clusters with targeted markers and 1000% better at capturing cells without them.
Researchers studied 293 patients with brain metastases and blood clots to determine if administering blood-thinning medication was safe. The study found no significant difference in bleeding risk between patients who received a widely used blood thinner and those who did not.
A new blood test has been developed to detect breast cancer metastasis significantly earlier than current methods, according to researchers at Lund University. The test uses circulating tumor DNA in the blood to identify genetic mutations specific to each tumor.
Researchers have developed nanoparticles carrying siRNA to silence the β3 integrin gene, which regulates cancer cell spread. The treatment significantly inhibited metastasis in mouse models, including five mice with human triple-negative breast cancer.
Researchers at Karolinska Institutet have discovered how cancer cells can infiltrate the lymphatic system by mimicking immune cells. This finding may lead to the development of new treatments targeting metastasis via the lymphatic system.
A study published in the Journal of Leukocyte Biology suggests that pre-existing inflammation can promote the spread of cancer by raising levels of chitinase-3-like-1, a known biomarker of cancer. This increase in CHI3L1 leads to faster cancer growth and increased metastasis.
Researchers at Harvard Medical School have developed an imageable mouse model of brain-metastatic breast cancer and shown the potential of a stem-cell-based therapy to eliminate metastatic cells from the brain and prolong survival. The study also describes a strategy to prevent negative consequences of stem cell therapy.
Researchers developed an imageable mouse model of brain-metastatic breast cancer and tested a stem-cell-based therapy that eliminates metastatic cells from the brain, prolonging survival. The treatment also prevents negative consequences by targeting tumor-specific molecules.
Researchers discovered a molecular mechanism connecting breast tissue stiffness to tumor metastasis and poor prognosis. High stiffness causes TWIST1 protein to lose its anchor, enabling cancer cells to invade surrounding tissue and metastasize.
Breast cancer cells can survive detachment from the extracellular matrix by forming multicellular aggregates, stabilizing EGFR protein. Elevated Bim-EL protein in inflammatory breast cancer cells blocks anoikis through complex with Beclin-1 and LC8.
Researchers at Houston Methodist have developed a new, ex vivo lung cancer model that mimics the process of tumor progression. The '4-D' model allows for the study of cancer metastasis, including the growth of primary tumors and formation of circulating tumor cells, providing insights into tumor progression and potential new therapies.
Researchers have linked a new protein, megalin, to aggressive malignant melanoma cells that are more likely to spread. The protein's presence can improve cancer cell division and survival, making it a potential marker for early detection and targeted treatment options.
Researchers at UC San Diego School of Medicine discovered G proteins signaling on membranes inside cells, controlling Golgi trafficking and enzyme secretion. Inhibition of protein GIV was shown to delay enzyme secretion and inhibit key cancer-driving signals.
Researchers developed a microfluidic chip that uses sound waves to separate circulating tumor cells from white blood cells, achieving a throughput rate up to 20 times faster than prior attempts. The device preserves the integrity of separated CTCs and offers a label-free approach without chemically altering the cells.
A new study found that cells within metastases from prostate tumors can migrate to other body parts and form new sites of spread on their own. This challenges the long-held belief that cells with metastatic potential originate solely from the original tumor site.
Breast tumors trick immune cells to produce neutrophils that block T-cell action, allowing cancer to spread. Anti-IL17 drugs already exist for inflammatory diseases, offering potential treatment for metastatic breast cancer.